109 related articles for article (PubMed ID: 38599661)
1. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
2. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Wang H; Borlongan M; Kaufman HL; Le U; Nauwynck HJ; Rabkin SD; Saha D
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821716
[TBL] [Abstract][Full Text] [Related]
4. oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy.
Sahu U; Mullarkey MP; Pei G; Zhao Z; Hong B; Kaur B
Mol Ther Oncolytics; 2023 Jun; 29():30-41. PubMed ID: 37114074
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
6. Targeting IGF2-IGF1R Signaling to Reprogram the Tumor Microenvironment for Enhanced Viro-Immunotherapy.
Noh MH; Kang JM; Miller AA; Nguyen G; Huang M; Shim JS; Bueso-Perez AJ; Murphy SA; Rivera-Caraballo KA; Otani Y; Kim E; Yoo SH; Yan Y; Banasavadi-Siddegowda Y; Nakashima H; Chiocca EA; Kaur B; Zhao Z; Lee TJ; Yoo JY
Neuro Oncol; 2024 Jun; ():. PubMed ID: 38853689
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of HLA-II related to LAG-3
Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
[TBL] [Abstract][Full Text] [Related]
8. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology.
Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B
J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741
[TBL] [Abstract][Full Text] [Related]
9. CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.
Pourchet A; Fuhrmann SR; Pilones KA; Demaria S; Frey AB; Mulvey M; Mohr I
EBioMedicine; 2016 Mar; 5():59-67. PubMed ID: 27077112
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression.
Tritz ZP; Ayasoufi K; Wolf DM; Owens CA; Malo CS; Himes BT; Fain CE; Goddery EN; Yokanovich LT; Jin F; Hansen MJ; Parney IF; Wang C; Moynihan KD; Irvine DJ; Wittrup KD; Diaz Marcano RM; Vile RG; Johnson AJ
Cancer Immunol Res; 2023 Jun; 11(6):763-776. PubMed ID: 36921098
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy with vaccine and oncolytic HSV virotherapy is time dependent.
Totsch SK; Ishizuka AS; Kang KD; Gary SE; Rocco A; Fan AE; Zhou L; Valdes PA; Lee S; Li J; Peruzzotti-Jametti L; Blitz S; Garliss CM; Johnston JM; Markert JM; Lynn GM; Bernstock JD; Friedman GK
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38710101
[TBL] [Abstract][Full Text] [Related]
12. The Oncolytic virus VT1092M and an Anti-PD-L1 antibody synergize to induce systemic antitumor immunity in a murine bilateral tumor model.
Zhu W; Shao M; Tian C; Yang J; Zhou H; Liu J; Sun C; Liu M; Wang J; Wei L; Li S; Li X; Li J
Transl Oncol; 2024 Jun; 46():102020. PubMed ID: 38843659
[TBL] [Abstract][Full Text] [Related]
13. Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma.
Lee J; Nicosia M; Hong ES; Silver DJ; Li C; Bayik D; Watson DC; Lauko A; Kay KE; Wang SZ; Johnson S; McGraw M; Grabowski MM; Kish DD; Desai AB; Goodman WA; Cameron SJ; Okada H; Valujskikh A; Fairchild RL; Ahluwalia MS; Lathia JD
Cancer Discov; 2023 Sep; 13(9):2090-2105. PubMed ID: 37378557
[TBL] [Abstract][Full Text] [Related]
14. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.
Ahn DH; Bekaii-Saab T
Biomedicines; 2017 Mar; 5(1):. PubMed ID: 28536353
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming the tumor microenvironment leverages CD8
Mistarz A; Winkler M; Battaglia S; Liu S; Hutson A; Rokita H; Gambotto A; Odunsi KO; Singh PK; McGray AJR; Wang J; Kozbor D
Mol Ther Oncolytics; 2023 Mar; 28():230-248. PubMed ID: 36875325
[TBL] [Abstract][Full Text] [Related]
16. Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8
Bai W; Tang X; Xiao T; Qiao Y; Tian X; Zhu B; Chen J; Chen C; Li Y; Lin X; Cai J; Lin Y; Zhu W; Yan G; Liang J; Hu J
Mol Ther Oncol; 2024 Jun; 32(2):200813. PubMed ID: 38817541
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer.
Kober C; Weibel S; Rohn S; Kirscher L; Szalay AA
Mol Ther Oncolytics; 2015; 2():15009. PubMed ID: 27119106
[TBL] [Abstract][Full Text] [Related]
18. Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus.
Finizio A; Pagano P; Napolano A; Froechlich G; Infante L; De Chiara A; Amiranda S; Vitiello E; Totaro S; Capasso C; Raia M; D'Alise AM; de Candia P; Zambrano N; Sasso E
Cancer Gene Ther; 2024 Jun; ():. PubMed ID: 38839891
[TBL] [Abstract][Full Text] [Related]
19. The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment.
Cannon A; Pajulas A; Kaplan MH; Zhang J
J Interferon Cytokine Res; 2023 Jun; 43(6):229-245. PubMed ID: 37319357
[TBL] [Abstract][Full Text] [Related]
20. Uncovering transcriptomic landscape alterations of CAN-2409 in
Koch MS; Zdioruk M; Nowicki MO; Hoetker MS; Herbert ZT; Barone F; Tak PP; Chiocca EA; Tabatabai G; Lawler SE
Front Med (Lausanne); 2023; 10():1140352. PubMed ID: 37228396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
